Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting

• Egile Nagusiak: Giovanna Ferrara (Egilea), Greta Mastrangelo (Egilea), Patrizia Barone (Egilea), Francesco La Torre (Egilea), Silvana Martino (Egilea), Giovanni Pappagallo (Egilea), Angelo Ravelli (Egilea), Andrea Taddio (Egilea), Francesco Zulian (Egilea), Rolando Cimaz (Egilea), On behalf of the Rheumatology Italian Study Group (Egilea)
• Formatua: Liburua
• Argitaratua: BMC, 2018-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background Conventional pharmacological therapies for the treatment of juvenile idiopathic arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among which methotrexate (MTX) is the most commonly prescribed. However, there is a lack of consensus-based clinical a...